“Dravet Syndrome Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Dravet Syndrome Market.
The Dravet Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Dravet Syndrome Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the emerging therapies for the treatment of Dravet Syndrome and the aggregate therapies developed by major pharma companies.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Dravet Syndrome market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage products (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Dravet Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Products have been categorized under various Molecule types, such as
Recombinant fusion proteins
Mechanism of Action of the Emerging Pipeline Therapies
NAV1.1 voltage-gated sodium channel modulators
Vitamin K replacements
Cholesterol 24-hydroxylase inhibitors; NMDA receptor modulators
Serotonin 2C receptor agonists
NAV1.1 voltage-gated sodium channel modulators; RNA interference
GABA A receptor agonists
Serotonin receptor modulators
TYK2 kinase inhibitors
Learn How the Ongoing Clinical & Commercial Activities will Affect the Dravet Syndrome Therapeutic Segment @
Dravet Syndrome Therapeutics Landscape
Several major pharma and biotech companies are developing therapies for Dravet Syndrome. Currently, Takeda is leading the therapeutics market with its Dravet Syndrome drug candidates in the most advanced stage of clinical development.
The Leading Players in the Dravet Syndrome Therapeutics Market Include:
And Many Others
Dravet Syndrome Emerging and Marketed Drugs Covered in the Report Include:
EPX-100: Epygenix Therapeutics
STK-001: Stoke Therapeutics
LP352: Longboard Pharmaceuticals
BMB 101: Bright Minds Biosciences
NT102: Neuroene Therapeutics
STK 001: Stoke Therapeutics
Diazepam : XERIS Pharmaceuticals
Lorcaserin: Eisai Inc
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Dravet Syndrome Current Treatment Patterns
4. Dravet Syndrome – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Dravet Syndrome Late Stage Products (Phase-III)
7. Dravet Syndrome Mid-Stage Products (Phase-II)
8. Dravet Syndrome Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Dravet Syndrome Discontinued Products
13. Dravet Syndrome Product Profiles
14. Key Companies in the Dravet Syndrome Market
15. Key Products in the Dravet Syndrome Therapeutics Segment
16. Dormant and Discontinued Products
17. Dravet Syndrome Unmet Needs
18. Dravet Syndrome Future Perspectives
19. Dravet Syndrome Analyst Review
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Explore the Key Offerings of the Report
Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States